News headlines about Mesoblast (NASDAQ:MESO) have been trending somewhat negative on Sunday, according to Accern Sentiment. Accern rates the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Mesoblast earned a media sentiment score of -0.01 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.9181973266237 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
MESO has been the topic of a number of research reports. Maxim Group set a $14.00 price objective on Mesoblast and gave the company a “buy” rating in a report on Wednesday, November 15th. Zacks Investment Research lowered Mesoblast from a “buy” rating to a “hold” rating in a report on Wednesday, November 1st. Oppenheimer set a $16.00 price objective on Mesoblast and gave the company a “buy” rating in a report on Tuesday, November 14th. Finally, Cantor Fitzgerald set a $20.00 price objective on Mesoblast and gave the company a “buy” rating in a report on Tuesday, January 16th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $13.11.
Shares of Mesoblast (MESO) traded down $0.11 on Friday, hitting $5.10. The stock had a trading volume of 33,745 shares, compared to its average volume of 43,925. Mesoblast has a 1 year low of $4.74 and a 1 year high of $12.50. The stock has a market capitalization of $469.33, a P/E ratio of -6.21 and a beta of 2.23.
TRADEMARK VIOLATION WARNING: “Mesoblast (MESO) Earning Somewhat Critical Media Coverage, Analysis Finds” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/18/mesoblast-meso-receiving-somewhat-negative-media-coverage-report-shows.html.
Mesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.